ATHEROSCLEROSIS / BASIC RESEARCH
The underlying mechanisms of FGF2 in carotid atherosclerotic plaque development revealed
by bioinformatics analysis
More details
Hide details
1
Department of Geriatrics, Tongji Hospital Affiliated to Tongji University Medical School, Shanghai, China
2
Jiading District Nanxiang Town Community Health Service Center, Affiliated to Tongji University Medical School, Shanghai, China
Submission date: 2020-01-12
Final revision date: 2020-09-30
Acceptance date: 2020-10-12
Online publication date: 2021-05-09
Publication date: 2024-08-04
Corresponding author
Wenlin Ma
Geriatrics Department,
Tongji Hospital Affiliated
to Tongji University Medical
School,
No. 389 Xincun Road, Putuo
District,
Shanghai 200065, China,
Phone: +86-021-66111457
Arch Med Sci 2024;20(4):1209-1219
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The purpose of this study was to explore the regulatory mechanisms of FGF2 on carotid atherosclerotic plaque development using bioinformatics analysis.
Material and methods:
Expression profiles of 32 atheroma plaque (AP) and 32 paired distant macroscopically intact (DMI) tissues samples in the GSE43292 dataset were downloaded from the Gene Expression Omnibus database. Following identification of differential expression genes (DEGs),
correlation analysis of fibroblast growth factor 2 (FGF2) and DEGs was conducted. Subsequently, functional enrichment analysis and the proteinprotein interaction network for FGF2 significantly correlated DEGs were constructed. Then, microRNAs (miRNAs) that regulated FGF2 and regulatory pairs of long noncoding RNA (lncRNA)-miRNA were predicted to construct the lncRNA-miRNA-FGF2 network.
Results:
A total of 101 DEGs between AP and DMI samples were identified, and 31 DEGs were analyzed to have coexpression relationships with FGF2, including 23 positively correlated and 8 negatively correlated DEGs. VAV3 had the lowest r value among all FGF2 negatively correlated DEGs. FGF2 positively correlated DEGs were closely related to “regulation of smooth muscle contraction” (e.g., calponin 1 [CNN1]), while FGF2 negatively correlated
DEGs were significantly associated with “platelet activation” (e.g., Vav guanine nucleotide exchange factor 3 [VAV3]). In addition, a total of 12 miRNAs that regulated FGF2 were predicted, and hsa-miR-15a-5p and hsamiR-16-5p were highlighted in the lncRNA-miRNA-FGF2 regulatory network.
Conclusions:
CNN1 might cooperate with FGF2 to regulate smooth muscle contractility during CAP formation. VAV3 might cooperate with FGF2 to be responsible for the development of CAP through participating in platelet activation. Hsa-miR-15a-5p and hsa-miR-16-5p might participate in the development of CAP via regulating FGF2.
REFERENCES (46)
1.
Chen Z, Ichetovkin M, Kurtz M, et al. Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability. Lipids Health Dis 2010; 9: 61.
2.
Can Y, Kocayigit I. Does contralateral carotid artery occlusion affect the clinical and long-term outcomes of carotid artery stenting? Arch Med Sci Atheroscler Dis 2020; 5: 13-9.
3.
Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012; 220: 128-33.
4.
Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke 2005; 36: 253-7.
5.
Xin Y, Y D. Research progress on the risk factors and clinical significance of carotid atherosclerosis. Medical Recapitulate 2015; 21: 239-41.
6.
Atkins PW, Perez HA, Spence JD, Muñoz SE, Armando LJ, García NH. Increased carotid plaque burden in patients with family medical history of premature cardiovascular events in the absence of classical risk factors. Arch Med Sci 2019; 15: 1388-96.
7.
Cheng HG, Patel BS, Martin SS, et al. Effect of comprehensive cardiovascular disease risk management on longitudinal changes in carotid artery intima-media thickness in a community-based prevention clinic. Arch Med Sci 2016; 12: 728-35.
8.
Bots M, Launer L, Lindemans J, Hofman A, Grobbee D. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam Study. J Intern Med 1997; 242: 339-47.
9.
Six I, Mouquet F, Corseaux D, et al. Protective effects of basic fibroblast growth factor in early atherosclerosis. Growth Factors 2004; 22: 157-67.
10.
Liang W, Wang Q, Ma H, Yan W, Yang J. Knockout of low molecular weight FGF2 attenuates atherosclerosis by reducing macrophage infiltration and oxidative stress in mice. Cell Physiol Biochem 2018; 45: 1434-43.
11.
Presta M, Foglio E, Churruca Schuind A, Ronca R. Long pentraxin-3 modulates the angiogenic activity of fibroblast growth factor-2. Front Immunol 2018; 9: 2327.
12.
Sigala F, Savvari P, Liontos M, et al. Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-kappaB pathway. J Cell Mol Med 2010; 14: 2273-80.
13.
Sapienza P, di Marzo L, Borrelli V, et al. Basic fibroblast growth factor mediates carotid plaque instability through metalloproteinase-2 and -9 expression. Eur J Vasc Endovasc Surg 2004; 28: 89-97.
14.
Liu W, Zhao Y, Wu J. Gene expression profile analysis of the progression of carotid atherosclerotic plaques. Mol Med Rep 2018; 17: 5789-95.
15.
Ayari H, Bricca G. Identification of two genes potentially associated in iron-heme homeostasis in human carotid plaque using microarray analysis. J Biosci 2013; 38: 311-5.
16.
Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64.
17.
Smyth GK. Limma: Linear Models for Microarray Data. In: Gentleman R, Carey VJ, Huber W, et al. (eds.). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer, New York 2005. p. 397-420.
18.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
19.
Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 2000; 28: 27-30.
20.
Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. Nat Genet 2000; 25: 25-9.
21.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16: 284-7.
22.
Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43 (Database issue): D447-52.
23.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504.
24.
Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 2015; 12: 697.
25.
Paraskevopoulou MD, Vlachos IS, Karagkouni D, et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res 2015; 44: D231-8.
26.
Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22: 32-9.
27.
Malhotra R, Mauer AC, Cardenas CLL, et al. HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype. Nat Genet 2019; 51: 1580-7.
28.
Perisic Matic L, Rykaczewska U, Razuvaev A, et al. Phenotypic modulation of smooth muscle cells in atherosclerosis is associated with downregulation of LMOD1, SYNPO2, PDLIM7, PLN, and SYNM. Arterioscler Thromb Vasc Biol 2016; 36: 1947-61.
29.
Liu R, Jin JP. Calponin isoforms CNN1, CNN2 and CNN3: regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells. Gene 2016; 585: 143-53.
30.
Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83: 361-6.
31.
Guo S, Cheng Y, Sun P. Effects of auricularia auricula polysaccharide on the phenotypes of vascular smooth muscle cells and the expression of bFGF and PDGF in atherogenesis. J Trop Med 2009; 9: 868-70.
32.
Akasaka Y, Ono I, Tominaga A, et al. Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of alpha-smooth muscle actin, leading to reduction of wound contraction. Wound Repair Regen 2007; 15: 378-89.
33.
Schober LJ, Khandoga AL, Dwivedi S, et al. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood. J Thromb Thrombolysis 2011; 32: 158-66.
34.
Yazdani MR, Khosropanah S, Doroudchi M. Interleukin-17 production by CD4+CD45RO+Foxp3+ T cells in peripheral blood of patients with atherosclerosis. Arch Med Sci Atheroscler Dis 2019; 4: e215-24.
35.
Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
36.
Toumaniantz G, Ferland-McCollough D, Cario-Toumaniantz C, Pacaud P, Loirand G. The Rho protein exchange factor Vav3 regulates vascular smooth muscle cell proliferation and migration. Cardiovasc Res 2010; 86: 131-40.
37.
Pearce AC, Senis YA, Billadeau DD, Turner M, Watson SP, Vigorito E. Vav1 and vav3 have critical but redundant roles in mediating platelet activation by collagen. J Biol Chem 2004; 279: 53955-62.
38.
Hayon Y, Dashevsky O, Shai E, Brill A, Varon D, Leker R. Platelet microparticles induce angiogenesis and neurogenesis after cerebral ischemia. Curr Neurovasc Res 2012; 9: 185-92.
39.
Hayon Y, Dashevsky O, Shai E, Varon D, Leker R. Platelet microparticles promote neural stem cell proliferation, survival and differentiation. J Mol Neurosci 2012; 47: 659-65.
40.
He Q, Ren X, Chen J, et al. miR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways. Oncotarget 2016; 7: 3047.
41.
Bidzhekov K, Gan L, Denecke B, et al. microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans. Thromb Haemost 2012; 107: 619-25.
42.
Lee JK, Park SR, Jung BK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One 2013; 8: e84256.
43.
Zheng X, Li A, Zhao L, et al. Key role of microRNA-15a in the KLF4 suppressions of proliferation and angiogenesis in endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 2013; 437: 625-31.
44.
Kinsella MG, Irvin C, Reidy MA, Wight TN. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 2004; 175: 51-7.
45.
Yin KJ, Olsen K, Hamblin M, Zhang J, Schwendeman SP, Chen YE. Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. J Biol Chem 2012; 287: 27055-64.
46.
Mao Y, Liu XQ, Song Y, Zhai CG, Xu XL. Fibroblast growth factor-2/platelet-derived growth factor enhances atherosclerotic plaque stability. J Cell Mol Med 2020; 24: 1128-40.